Article

Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes.

Department of Pathology, University of Pittsburgh School of Medicine, PA, USA.
Human Pathlogy (Impact Factor: 2.81). 11/2003; 34(10):1030-4. DOI: 10.1053/S0046-8177(03)00410-6
Source: PubMed

ABSTRACT Mantle cell lymphoma (MCL) is typically considered an aggressive but incurable neoplasm composed of cyclin D1+ monoclonal B-cells with a t(11;14)(q13;q32) and usually unmutated immunoglobulin (Ig) genes. Although it has been suggested that a more indolent leukemic disorder exists with the same phenotype and genotype but with mutated Ig genes, others have considered these cases to be variants of chronic lymphocytic leukemia. We present a case of an indolent MCL that was documented with cyclin D1 expression in a lymph node biopsy performed more than 12 years ago. The patient has peripheral blood involvement with a lymphocyte count in the reference range, variable thrombocytopenia, and minimal adenopathy but is otherwise well, never having received any antineoplastic therapy. Study of peripheral blood samples from 2002 revealed a CD5-variable B-cell monoclonal proliferation with a t(11;14)(q13;q32) plus other karyotypic abnormalities, positive fluorescence in situ hybridization studies for the CCND1/IgH translocation, and clonal Ig gene rearrangement with mutated Ig genes (95.7% homology to VH 4-31). The subtle but diagnostic lymph node biopsy in this case helps to further support that an indolent t(11;14) monoclonal lymphocytosis with mutated Ig genes can represent an MCL variant rather than chronic lymphocytic leukemia.

0 Bookmarks
 · 
72 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Over the past decade, it has become increasingly clear that mantle cell lymphoma (MCL) is a more heterogeneous disease than originally recognized. Several groups have reported on a subgroup of patients with a less aggressive course than expected resulting in the term “indolent MCL”. Unlike the recognized histologic variants, the definition of indolent mantle cell lymphoma is unclear, and patients with indolent MCL are often identified only after having undergone prolonged periods of observation. In this review, we will discuss clinical and biologic features and provide a framework for the approach in identifying patients with indolent MCL.
    Leukemia and Lymphoma 03/2014; 55(4). · 2.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A 65-year-old gentleman presented with left groin swelling over the course of two months. Physical exam revealed nontender left inguinal adenopathy, and computed tomography scans detected multiple lymph nodes in the mesenteric, aortocaval, and right common iliac regions. An excisional lymph node biopsy was performed. Pathologic evaluation demonstrated follicular center site which stained positive for PAX5, CD20, CD10, Bcl-2, Bcl-6, and mantle zone cells. These findings demonstrated CCND1 and CD5 positivity, suggesting composite lymphoma comprising follicular lymphoma (FL) with in situ mantle cell lymphoma (MCLIS). FL is known as indolent non-Hodgkin lymphoma; however, the clinical significance of a coexisting MCLIS continues to be elusive, and optimal management of these patients remains largely unknown. This case illustrates the diagnostic and therapeutic challenges of composite lymphomas. This paper also discusses advances in molecular pathogenesis and lymphoma genomics which offer novel insights into these rare diseases.
    Case reports in hematology. 01/2014; 2014:145129.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Die 2008 aktualisierte WHO-Klassifikation der lymphatischen Neoplasien stellt einen weltweiten Konsensus über die Diagnose dieser Tumoren dar. Sie basiert auf einem multidisziplinären Ansatz zur Definition von eigenständigen Lymphomentitäten. Bekannte Lymphomkrankheiten wurden genauer definiert, neue Entitäten identifiziert sowie neue Konzepte und Erkenntnisse, die zu einem besseren Verständnis der malignen Lymphome beitragen, integriert. Eine Reihe von Fragen blieben allerdings ungelöst. Zu diesen gehörten insbesondere die Frage, welcher Grad genetischer oder molekularer Veränderungen für die Definition einer eigenständigen Lymphomentität notwendig ist und der Status der provisorischen Entitäten. In der Zeit nach der Veröffentlichung der WHO-Klassifikation von 2008 gab es eine Reihe neuer wissenschaftlicher Beobachtungen. Außerdem wurden neue Konzepte zum Verständnis der malignen Lymphome entwickelt. Dieser Fortschritt ist der Schwerpunkt nach folgender Übersicht, soweit er Einfluss auf die diagnostischen Kriterien hat.
    Der Onkologe 01/2011; 17(9). · 0.13 Impact Factor